Quadramet (Samarium-153 Lexidronam)

What Is Quadramet and What Is It Used For?

Quadramet (samarium-153 lexidronam) is a therapeutic radiopharmaceutical used to relieve bone pain in adults with multiple painful osteoblastic bone metastases that take up the radioactive tracer bisphosphonate on diagnostic bone scans. It is most commonly used in metastatic prostate cancer, breast cancer, lung cancer, and other tumours that produce osteoblastic bone lesions.

Quadramet represents a specialised form of cancer treatment known as systemic targeted radionuclide therapy. Rather than delivering radiation from outside the body, as in conventional external beam radiotherapy, Quadramet is injected into a vein and travels through the bloodstream to the skeleton. Once there, it concentrates selectively at sites where bone is forming or remodelling rapidly — a hallmark of metastatic bone lesions from many cancers.

The active substance is samarium (¹⁵³Sm) lexidronam pentasodium, sometimes abbreviated as ¹⁵³Sm-EDTMP. It is a chemical complex consisting of radioactive samarium-153 bound to ethylenediaminetetramethylenephosphonate (EDTMP), a molecule that binds strongly to the mineralised matrix of bone. Samarium-153 is a beta-emitting radionuclide with a relatively short physical half-life of 46.3 hours, which means the radioactivity decays quickly after treatment is complete.

Bone metastases are a common and often devastating complication of advanced cancer. According to the World Health Organization and international oncology guidelines, approximately 65–75% of patients with metastatic prostate or breast cancer develop bone involvement during their disease. Bone metastases frequently cause severe, persistent pain that significantly impairs mobility, quality of life, and the ability to tolerate active anticancer treatment. Quadramet is one of several options available to reduce this pain as part of a comprehensive palliative care strategy.

How Quadramet Works

When Quadramet is injected into the bloodstream, the EDTMP component acts as a carrier molecule that chemically resembles naturally occurring bisphosphonates. It binds preferentially to hydroxyapatite, the calcium-phosphate mineral that makes up bone matrix. At sites of active bone turnover — such as the reactive new bone that forms around osteoblastic metastases — this binding is particularly strong, resulting in a tumour-to-normal bone uptake ratio that is typically around 5 to 1.

Once Quadramet has deposited in bone, the radioactive samarium-153 nucleus decays and emits beta particles with a maximum energy of 810 keV. These high-energy electrons travel only a few millimetres through tissue, delivering their radiation dose primarily to the metastatic lesion and the immediately surrounding bone. Samarium-153 also emits a small amount of 103-keV gamma radiation (28% abundance), which can be detected by a gamma camera. This dual property allows clinicians to image the distribution of Quadramet after treatment and confirm that it has concentrated appropriately in the intended target areas.

The precise mechanism by which Quadramet relieves pain is not fully understood. Current evidence suggests several contributing factors: direct radiation-induced reduction of tumour size and associated pain-generating inflammation, disruption of neurochemical pain signalling from nerve endings in the periosteum, and modulation of bone turnover at the tumour-bone interface. The analgesic effect usually begins within 1 to 2 weeks, peaks around 3 to 4 weeks, and can last from several weeks to several months.

Clinical Use and Approval

Quadramet received marketing authorisation from the U.S. Food and Drug Administration (FDA) in 1997 and from the European Medicines Agency (EMA) in 1998. It is approved for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium-99m-labelled bisphosphonates on diagnostic bone scans. This condition is common in advanced metastatic castration-resistant prostate cancer, metastatic breast cancer, and certain other malignancies including non-small cell lung cancer and osteosarcoma.

Quadramet is administered exclusively in authorised nuclear medicine departments by physicians and technologists trained in the safe handling of unsealed radioactive sources. Before treatment, a whole-body bone scintigraphy using technetium-99m-methylene diphosphonate (^99mTc-MDP) is required to confirm that the patient's bone lesions will concentrate the phosphonate tracer. This is a prerequisite because the therapeutic effect of Quadramet depends on the same uptake mechanism.

What Should You Know Before Taking Quadramet?

Before receiving Quadramet, your medical team will check your recent blood counts, bone scan findings, renal function, and overall fitness for treatment. You must not receive Quadramet if you are pregnant, breastfeeding, have severe bone marrow failure, or have received myelosuppressive chemotherapy or wide-field external beam radiotherapy in the preceding six to eight weeks.

Quadramet is a powerful radiopharmaceutical that requires careful patient selection and preparation. Your nuclear medicine physician will review your oncology history, previous treatments, and current health status to determine whether Quadramet is appropriate for you. Because the therapy produces predictable bone marrow suppression, your recent and planned cancer treatments are particularly important. Understanding the precautions and contraindications in detail helps ensure your safety and the success of treatment.

Contraindications

You must not receive Quadramet in the following circumstances:

• Hypersensitivity to samarium-153 lexidronam, EDTMP or other related phosphonates, or to any of the excipients in the formulation
• Pregnancy: Quadramet is contraindicated in women who are pregnant or may be pregnant because ionising radiation can harm the developing fetus
• Breastfeeding: The radionuclide is excreted in breast milk; breastfeeding must be discontinued if Quadramet is considered essential
• Severe bone marrow suppression — patients with white blood cell count < 2.5 × 10⁹/L, platelets < 60 × 10⁹/L, or documented inadequate marrow reserve
• Recent myelosuppressive therapy: Chemotherapy or wide-field external beam radiotherapy within the preceding 6–8 weeks
• Spinal cord compression from bone metastases — this constitutes a neurosurgical or radiotherapy emergency and takes priority over Quadramet
• Evidence of disseminated intravascular coagulation (DIC) or other uncorrected bleeding disorders

Warnings and Precautions

Talk to your doctor before receiving Quadramet if any of the following apply to you:

• Reduced kidney function: Quadramet is excreted predominantly through the kidneys, and severe renal impairment can prolong radioactivity in the body and increase bladder and bone marrow exposure. Adequate hydration and, in some cases, a dose reduction may be considered
• Urinary obstruction or incontinence: Because radioactive urine is produced for approximately 6–12 hours after injection, urinary retention can lead to higher bladder dose. A urinary catheter may be required for patients unable to void reliably
• Baseline cytopenias: If blood counts are already low due to prior treatment, further reductions after Quadramet may be clinically significant
• Planned future chemotherapy or external beam radiotherapy: Bone marrow toxicity from Quadramet can delay or limit subsequent treatments; careful scheduling is required
• Diffuse marrow involvement by cancer: Patients with very extensive (superscan) bone metastases may have reduced marrow reserve and greater cytopenia risk
• Children and adolescents: Safety and efficacy in patients under 18 years have not been fully established outside selected indications such as osteosarcoma in clinical protocols

Tests and Monitoring Before Treatment

Before you receive Quadramet, your nuclear medicine and oncology team will perform a comprehensive evaluation, which typically includes:

• Recent whole-body ^99mTc-bisphosphonate bone scan to confirm that bone lesions take up the phosphonate tracer (an essential prerequisite for Quadramet to be effective)
• Complete blood count including white blood cell count, absolute neutrophil count, haemoglobin, and platelet count
• Renal function tests (serum creatinine, estimated glomerular filtration rate) and serum calcium
• Review of current pain severity, analgesic requirements, and functional status
• Assessment for spinal cord compression risk, including neurological examination and, where indicated, spinal MRI
• Pregnancy test in women of reproductive potential
• Review of all recent and planned anticancer therapies

After treatment, your blood counts will be monitored at least weekly for 8 weeks, and more frequently if severe cytopenias develop. Clinical pain assessment and medication review should be continued throughout the follow-up period to evaluate response and guide ongoing management.

Pregnancy, Breastfeeding, and Fertility

Quadramet is contraindicated during pregnancy. Ionising radiation from the radionuclide can cause fetal harm. Women of reproductive age must use effective contraception during treatment and for a period advised by their medical team afterwards. If pregnancy occurs during or shortly after treatment, the absorbed dose to the fetus should be assessed by a medical physicist to guide individual counselling.

• Breastfeeding must be discontinued if Quadramet is administered, because the radionuclide is excreted in breast milk and could deliver radiation to the infant
• Fertility: Information about long-term effects on fertility is limited; however, gonadal radiation exposure may reduce fertility, particularly with repeated dosing. Male and female patients of reproductive age should discuss fertility preservation with their oncology team when relevant
• Men should avoid conceiving a child for a period recommended by their physician after Quadramet, typically at least several months

Driving and Operating Machinery

Quadramet is not known to directly affect the ability to drive or operate machinery. However, the pain, fatigue, and medication effects associated with advanced cancer — including concomitant opioids and other analgesics — may impair alertness. Patients should follow the general advice of their oncology team regarding driving safety.

Children and Adolescents

The safety and efficacy of Quadramet in children and adolescents under 18 years of age have not been comprehensively established in the approved labelling. Selected use in paediatric osteosarcoma has been described in specialised clinical protocols. Any paediatric use should take place within a specialist oncology setting with individualised dosimetry and strict informed consent.

How Does Quadramet Interact with Other Drugs?

Quadramet has relatively few direct pharmacological drug interactions, but its bone marrow toxicity overlaps with that of cytotoxic chemotherapy and external beam radiotherapy. Treatment sequencing with myelosuppressive drugs, other bone-targeting agents, and bisphosphonates must be carefully coordinated to avoid additive haematological toxicity.

Because Quadramet exerts its effect through localised radiation rather than conventional pharmacology, classical cytochrome P450-mediated drug interactions are not a major concern. However, several important clinical interactions relate to additive toxicity or competition for bone-binding sites. Always inform your oncology and nuclear medicine teams about every medicine you take, including prescription drugs, over-the-counter products, and dietary supplements.

Major Interactions

Minor Interactions

A number of agents may have a minor theoretical interaction or require practical coordination:

• Intravenous calcium preparations and parenteral nutrition — high circulating calcium can compete with Quadramet uptake; separating administration is reasonable
• Iron preparations — may interfere with binding if given intravenously in close proximity; oral iron is generally not a concern
• Diuretics — can alter urinary elimination of the radionuclide; ensure adequate hydration when used

What Is the Correct Dosage of Quadramet?

The recommended dose of Quadramet is 37 MBq per kilogram of body weight, administered as a single slow intravenous bolus injection over approximately one minute. The dose is prepared individually for each patient by a nuclear medicine pharmacy team based on the calibration time and weight at the day of treatment. Retreatment may be considered after a minimum of 8 weeks and only after full recovery of blood counts.

Quadramet is not taken at home and does not follow a conventional daily dosing schedule. Each dose is specifically prepared for an individual patient at the hospital radiopharmacy and administered under the direct supervision of a nuclear medicine physician. Because Quadramet decays at a predictable rate, the volume of solution required varies depending on the interval between calibration and injection.

Adults

Children

Elderly

Patients with Renal Impairment

Preparation for Injection

On the day of treatment, patients should follow the preparation instructions given by the nuclear medicine department:

• Hydrate well: Drink at least 500–1,000 mL of water or other clear fluids in the hours before injection, unless advised otherwise
• Empty the bladder immediately before injection and again approximately every hour for the first 6 hours afterwards
• Arrive with a list of current medications and recent blood-test results
• Wear comfortable clothing and plan for the appointment to last approximately 2–4 hours including preparation, injection, and observation
• Arrange transport, as patients should rest and avoid strenuous activity immediately after treatment

During Injection

The injection is given in a dedicated nuclear medicine procedure room. A patent intravenous cannula is flushed with saline before and after Quadramet to ensure the full dose is delivered. Patients remain in the department for a period of observation, during which vital signs and any immediate adverse reactions are monitored. A post-injection gamma-camera scan is sometimes performed to confirm appropriate distribution of the radiopharmaceutical within the skeleton.

Missed Appointments and Repeat Treatment

Because Quadramet is an individually prepared radiopharmaceutical with a fixed calibration time, missed appointments cannot be “made up” on a later day with the same dose; a new preparation is required. Contact the nuclear medicine department as soon as possible if you cannot keep your appointment so that the radiopharmacy can plan accordingly.

Repeat doses of Quadramet may be considered if pain recurs after initial response. Retreatment is typically not performed before 8 weeks have elapsed and only after blood counts have fully recovered. The decision to repeat treatment takes into account the duration of previous response, the pattern of disease progression, current blood counts, and the availability of other therapies. Repeat treatment has been well tolerated in clinical studies when appropriate spacing and monitoring are observed.

Overdose

An accidental overdose of Quadramet is extremely unlikely because the dose is prepared and measured precisely by a radiopharmacy using calibrated equipment. In the theoretical event of overdose, the principal risk is more severe and prolonged myelosuppression. Management is supportive and includes increased hydration, frequent voiding to accelerate renal excretion, intensive blood-count monitoring, and treatment of cytopenias with transfusion support, growth factors or antibiotics as required.

What Are the Side Effects of Quadramet?

The most common and expected side effect of Quadramet is a temporary decrease in blood cell counts, particularly platelets and white blood cells, occurring 3 to 5 weeks after injection and recovering within 8 weeks. A brief increase in bone pain in the first few days (“flare”) is also common. Most other side effects are mild and self-limiting, but serious cytopenias and rare long-term effects are possible.

Like all medicines, Quadramet can cause side effects, although not everyone will experience them. Because Quadramet delivers ionising radiation directly to bone, most significant adverse effects reflect the expected biological consequences of radiation on bone marrow. Understanding which side effects are common, which are serious, and when to seek medical help is an essential part of safe treatment.

Serious Side Effects

The following side effects have been reported with Quadramet. Frequencies are based on clinical trials and post-marketing surveillance; individual experience may vary:

Bone Marrow Suppression Explained

Reduction in blood cell counts is the most important and predictable side effect of Quadramet. Because the bone marrow sits within the skeleton, a proportion of the radiation delivered to bone metastases inevitably reaches nearby marrow cells, temporarily reducing their ability to produce new blood cells. Platelets typically fall first and most noticeably, followed by white blood cells. Red blood cell counts are less affected in the short term because mature red cells have a long lifespan in circulation.

In clinical trials, platelet and white blood cell counts decreased by an average of 40–50% from baseline, with the nadir (lowest point) reached at 3 to 5 weeks after injection. Most patients recover spontaneously, with counts returning to near baseline by week 8. Severe neutropenia or thrombocytopenia is uncommon in patients with adequate marrow reserve at baseline but can require transfusion, growth factor support, antibiotics, or delay of subsequent chemotherapy.

The Pain “Flare” Phenomenon

Between 10% and 20% of patients notice a transient increase in bone pain during the first 72 hours after Quadramet injection. This “flare” typically lasts from one to four days and then subsides, often followed by improvement below baseline pain levels. The flare is thought to reflect radiation-induced cellular changes at the tumour-bone interface. It is not a sign of treatment failure or disease progression. Pre-emptive adjustment of analgesics is reasonable, and your pain team should be informed so that breakthrough pain can be managed quickly.

Radiation Safety and Long-Term Risks

As with any exposure to ionising radiation, a small theoretical long-term risk of secondary malignancy exists. This risk is particularly considered in the context of patients with advanced metastatic cancer, where life expectancy and the benefit of effective pain control typically outweigh the theoretical risk. In the event of repeated dosing or combination with other marrow-toxic therapies, the risk of myelodysplastic syndrome and leukaemia should be discussed as part of informed consent.

Managing and Reporting Side Effects

Your oncology and nuclear medicine team will schedule blood tests and follow-up visits specifically to detect and manage expected side effects. Report any new or worsening symptoms promptly, including those that appear weeks after the injection. Many side effects are manageable with supportive care, and early intervention significantly improves outcomes. You can also report suspected adverse reactions to your national pharmacovigilance authority — doing so contributes to the continued monitoring of Quadramet's safety profile.

How Should You Store Quadramet?

Quadramet is stored and handled exclusively by the hospital radiopharmacy in shielded containers under strict radiation protection standards. It is kept frozen at −10°C to −20°C and thawed immediately before administration. Patients do not handle or store Quadramet themselves.

As a patient, you will not be responsible for storing Quadramet. The product is received, quarantined, prepared, and administered entirely by trained radiopharmacy and nuclear medicine personnel. However, understanding the storage requirements helps illustrate why Quadramet can only be used in approved centres and why appointment times must be kept precisely.

Quadramet is supplied as a frozen solution for injection in a lead-shielded container. Storage is at a controlled low temperature, typically −10°C to −20°C, in a dedicated radioactive materials freezer with access restricted to authorised personnel. The product is thawed at room temperature shortly before administration and must be used within the timeframe specified by the manufacturer; it should not be refrozen once thawed.

Because samarium-153 has a physical half-life of 46.3 hours, the radioactivity of each batch decreases by approximately half every two days. Quadramet is therefore supplied with a reference calibration date and time, and the activity at the time of injection is recalculated to decide the correct volume. The product is used only up to a defined expiry period after calibration, after which radioactivity levels are insufficient for therapeutic effect.

Transportation and disposal of Quadramet are subject to national radioactive materials regulations. Shielded waste containers, dedicated waste storage, and radiation monitoring are used throughout the process. Any residual activity in syringes, vials, or administration sets is disposed of as radioactive waste in accordance with local rules.

What Does Quadramet Contain?

Quadramet contains the active substance samarium (¹⁵³Sm) lexidronam pentasodium — a complex of radioactive samarium-153 with ethylenediaminetetramethylenephosphonate (EDTMP). The formulation also contains excess EDTMP as a stabiliser, calcium sodium salts, water for injections, and pH-adjusting agents.

The active ingredient of Quadramet is samarium (¹⁵³Sm) lexidronam pentasodium, which at the reference calibration date and time provides a specific activity of 1.3 GBq per millilitre of solution. The radionuclide samarium-153 has a half-life of 46.3 hours and emits beta particles (maximum energy 810 keV, accompanied by weaker beta energies) and a 103-keV gamma photon (approximately 28% abundance). The beta emissions are responsible for the therapeutic effect, while the gamma component allows post-therapy imaging to confirm correct skeletal distribution.

Excipients (Inactive Ingredients)

The formulation of Quadramet typically contains the following inactive ingredients:

• Excess EDTMP (ethylenediaminetetramethylenephosphonate) — chelating agent that stabilises the samarium-153 complex
• Calcium chloride or related calcium salts — used in the complexation process and to buffer the formulation
• Sodium hydroxide — used for pH adjustment
• Water for injections

Important Composition Notes

Because Quadramet is a radiopharmaceutical, specific radiochemical and chemical considerations apply:

• Radionuclide source: Samarium-153 is produced by neutron activation of enriched samarium-152 in a nuclear reactor, followed by chemical purification and complexation with EDTMP
• Physical half-life: 46.3 hours, meaning radioactivity has effectively decayed to background within 2–3 weeks
• Radiation emissions: beta particles (therapeutic) with a small gamma component (imaging)
• Sodium content: Low per dose; generally not clinically significant but should be noted for patients on severe sodium restriction
• Allergenic components: Rare hypersensitivity to phosphonate chelators is possible — report any previous bisphosphonate or EDTA allergy to your medical team

Appearance and Packaging

Quadramet is supplied as a clear, colourless to slightly amber frozen solution within a shielded multi-dose vial or unit-dose container appropriate for hospital radiopharmacy handling. Each vial is packaged in a lead shield to minimise radiation exposure to staff during storage, transport, and preparation. Patient-specific doses are drawn up on the day of treatment using shielded syringes and dose calibrators to verify the activity prior to injection.